서비스 업데이트

[Service Update] Jarame Sets a New Standard with AI Digital Care Log for Developmental Disabilities

After three years of development since 2022, Jarame solves fundamental limits in developmental disability care with AI—unifying fragmented data across hospital, center, school, and home.

Author: 드림에이아이랩

Archive notice

This article is preserved as a press/archive snapshot. For current product, business, and metrics, see:

Jarame: A New Standard in Developmental Disability Care

From "untreatable" to "treatable when we record" — powered by the world's first AI Digital Care Log

Why Jarame

Developmental disability care suffers from data silos, inequality, and weak cross-institution collaboration. Jarame uses AI to turn care records into actionable, personalized therapy—Dream AI Lab's first step toward AI for humanity's hardest welfare challenges.

Problems Jarame addresses

  • Missed golden-time intervention (ages 3–7)
  • Disconnected home, school, center, and hospital records
  • Unaffordable care without guaranteed outcomes
  • Subjective assessments instead of objective data

Jarame unifies care data in real time, applies multimodal AI and reinforcement learning, and supports personalized care plans validated across thousands of institutions.

Related tags

  • #자람이
  • #AI 디지털케어로그
  • #발달장애
  • #맞춤형 치료
  • #골든타임
  • #세계 최초
  • #데이터 통합
  • #AI 엔진
  • #치료 표준

Related articles

재가돌봄·주간보호에서 요양원·요양병원까지 이어지는 시니어앤라이프 돌봄 현장
보도자료

Senior & Life reports home-care registration reach and plans expansion into nursing facilities

Senior & Life reported a self-published registration and linkage pool of 10,000 home-care sites and 1,200 day-care centers. These figures are not the same as active deployments or independently verified market share; the current product is a Pilot.

Read more →
자람이 FDA 준비 개념도: 가정·센터 기록이 RWE 근거 계층을 거쳐 단일 치료 모듈 Therapeutic-01로 모이는 구조
보도자료

Jarame prepares an FDA pathway: 100,000-person RWD and a separated digital therapeutic module

Jarame will not file its whole platform as a medical device. It plans to isolate one therapeutic module for a U.S. FDA pathway. About 100,000 people of real-world data is a starting point, not an FDA-validated clinical result.

Read more →
자람이 FDA 분리 전략: 열린 플랫폼과 봉인된 치료 모듈이 경계벽으로 나뉜 개념도
기술 블로그

Keep the platform open, regulate only the therapy module: Jarame’s FDA strategy is separation

Jarame will not medical-device the whole platform. It isolates functions that directly affect treatment outcomes, and layers the AI Digital Care Log into source records, RWE, and a treatment engine.

Read more →